Imran Ahmad, MD, outlines the diagnosis and management of diabetic macular edema, emphasizing screening gaps, socioeconomic barriers, and treatment options in developing countries. He reviews evidence-based protocols, the role of anti-VEGF therapies like aflibercept, ranibizumab, and off-label bevacizumab, and how treatment choices shift when affordability and access are limited.
Sean Adrean, MD, Retina Consultants of Orange County, describes results from a post hoc analysis of the Phase 2/3 PHOTON trial investigating the impact of baseline visual acuity…
Charles C. Wykoff, MD, highlights both the success and the limitations of current treatments for wet AMD. While anti-VEGF therapies are effective at controlling bleeding and leakage in…
Jean-Francois Korobelnik, MD, professor of ophthalmology, University Hospital of Bordeaux, explained findings of an analysis of the Phase 3 PULSAR trial designed to assess disease activity control. Dr…
Omar Krad, MD, shares his practical approach to cataract surgery in patients with wet macular degeneration. This case involves a diabetic, hyperopic patient with vision limited to counting…
Kenneth C. Fan, MD, MBA, Retinal Consultants of Texas, discusses how increased doses of aflibercept can be used to treat patients with wet age-related macular degeneration and diabetic…
Mark R. Barakat, MD, founder and director of research, Retina Macula Institute of Arizona, discusses an analysis of the Phase 2/3 PHOTON trial. Dr Barakat explained that pre-dose…
In an interview conducted at the Association for Research in Vision and Ophthalmology Annual Meeting, May 5-9, 2023, Jordana Fein, MD, MS, Retina Group of Washington Fairfax, Virginia,…
Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes. It occurs when long-term high blood sugar damages retinal blood vessels, causing them…
Wet age-related macular degeneration (AMD) is a chronic, progressive eye disease marked by abnormal blood vessel growth beneath the retina. These fragile vessels can leak fluid or blood…
Starting diabetic macular edema treatment with bevacizumab and switching to aflibercept if needed offers nearly identical vision outcomes to aflibercept monotherapy, but at a far lower cost. A…
